Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study.

doi:10.1055/s-0040-1722623

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study.

Thrombosis and haemostasis - 1 Nov 2021

Liesner Ri J, Abraham Aby, Altisent Carmen, Belletrutti Mark J, Carcao Manuel, Carvalho Manuela, Chambost Hervé, Chan Anthony K C, Dubey Leonid, Ducore Jonathan, Gattens Michael, Gresele Paolo, Gruel Yves, Guillet Benoit, Jimenez-Yuste Victor, Kitanovski Lidija, Klukowska Anna, Lohade Sunil, Mancuso Maria Elisa, Oldenburg Johannes, Pavlova Anna, Pollio Berardino, Sigaud Marianne, Vdovin Vladimir, Vilchevska Kateryna, Wu John K M, Jansen Martina, Belyanskaya Larisa, Walter Olaf, Knaub Sigurd, Neufeld Ellis J

Abstract excerpt

INTRODUCTION: FVIII inhibitor development is the most serious contemporary treatment complication in haemophilia A, particularly in previously untreated patients (PUPs). No inhibitors developed in clinical trials in previously treated patients treated with simoctocog alfa (Nuwiq), a fourth-generation recombinant FVIII produced in a human cell line. METHODS: The NuProtect study investigated the immunogenicity of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Coagulants

Share to Factor VIII

Share to Hemophilia A

Share to Hemorrhage

Share to Recombinant Proteins

Share to Severity of Illness Index

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 33581698
DOI: 10.1055/s-0040-1722623
PMCID: PMC8570909

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study.PMID 33581698Read ↗

Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.Semantic proximity Read ↗

SIPPET: methodology, analysis and generalizabilitySemantic proximity Read ↗

Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A.Semantic proximity Read ↗

Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010.Semantic proximity Read ↗

The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom.Semantic proximity Read ↗

Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis.Semantic proximity Read ↗

Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet studySemantic proximity Read ↗

Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial.Semantic proximity Read ↗

Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis.Semantic proximity Read ↗

Inhibitor development in previously untreated patients with severe haemophilia A: a nationwide multicentre study in Finland.Semantic proximity Read ↗

In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study.Semantic proximity Read ↗

Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.